Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

GL-701 shows significant steroid-sparing effects in women with active SLE

Nov. 20, 1997

Synvisc introduced in U.S.

Nov. 20, 1997

Preliminary phase III data presented on celecoxib at arthritis symposium

Nov. 20, 1997

Enbrel phase III and long-term safety data presented at rheumatology meeting

Nov. 20, 1997

New VCAM-1 inhibitor isolated from marine sponge

Nov. 19, 1997

rhIL-11 effective in rats with adjuvant arthritis

Nov. 19, 1997

rhIL-10 evaluated for safety and efficacy in RA patients

Nov. 19, 1997

Complement activation inhibitors prepared at U of Pennsylvania

Nov. 19, 1997

Second-generation, highly selective COX-2 inhibitors developed at Merck

Nov. 18, 1997

Safety, immunogenicity and efficacy of anti-TNF antibody in RA patients

Nov. 18, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...